A Phase I/II. Open-Label, Multiple Dose Study of the Safety, Tolerability, and Pharmacokinetics of TAK-700 in Metastatic, Androgen-Independent Prostate Cancer Subjects.
Phase of Trial: Phase I/II
Latest Information Update: 13 Jan 2014
At a glance
- Drugs Orteronel (Primary) ; Prednisone
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors Takeda Oncology
- 10 Jun 2017 Biomarkers information updated
- 13 Jun 2013 Planned end date changed from 1 Feb 2013 to 1 Mar 2015 as reported by ClinicalTrials.gov.
- 23 Jan 2013 Planned end date changed from 1 Aug 2014 to 1 Feb 2013 as reported by ClinicalTrials.gov.